These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 23479184)

  • 61. Pharmacotherapies for sleep disturbances in dementia.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009178. PubMed ID: 27851868
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?
    Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F
    Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cortisol, Amyloid-β, and Reserve Predicts Alzheimer's Disease Progression for Cognitively Normal Older Adults.
    Udeh-Momoh CT; Su B; Evans S; Zheng B; Sindi S; Tzoulaki I; Perneczky R; Middleton LT;
    J Alzheimers Dis; 2019; 70(2):553-562. PubMed ID: 31256117
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Beyond the sleep-amyloid interactions in Alzheimer's disease pathogenesis.
    Ning S; Jorfi M
    J Neurophysiol; 2019 Jul; 122(1):1-4. PubMed ID: 30864847
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
    Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
    Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
    JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics.
    Lucey BP; Hicks TJ; McLeland JS; Toedebusch CD; Boyd J; Elbert DL; Patterson BW; Baty J; Morris JC; Ovod V; Mawuenyega KG; Bateman RJ
    Ann Neurol; 2018 Jan; 83(1):197-204. PubMed ID: 29220873
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
    Morris JC; Schindler SE; McCue LM; Moulder KL; Benzinger TLS; Cruchaga C; Fagan AM; Grant E; Gordon BA; Holtzman DM; Xiong C
    JAMA Neurol; 2019 Mar; 76(3):264-273. PubMed ID: 30615028
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease.
    Timmers M; Tesseur I; Bogert J; Zetterberg H; Blennow K; Börjesson-Hanson A; Baquero M; Boada M; Randolph C; Tritsmans L; Van Nueten L; Engelborghs S; Streffer JR
    Neurobiol Aging; 2019 Jul; 79():131-141. PubMed ID: 31055223
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The normal equilibrium between CSF and plasma amyloid beta levels is disrupted in Alzheimer's disease.
    Giedraitis V; Sundelöf J; Irizarry MC; Gårevik N; Hyman BT; Wahlund LO; Ingelsson M; Lannfelt L
    Neurosci Lett; 2007 Nov; 427(3):127-31. PubMed ID: 17936506
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration.
    Höglund K; Kern S; Zettergren A; Börjesson-Hansson A; Zetterberg H; Skoog I; Blennow K
    Transl Psychiatry; 2017 Jan; 7(1):e995. PubMed ID: 28072416
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effects of age and amyloid deposition on Aβ dynamics in the human central nervous system.
    Huang Y; Potter R; Sigurdson W; Santacruz A; Shih S; Ju YE; Kasten T; Morris JC; Mintun M; Duntley S; Bateman RJ
    Arch Neurol; 2012 Jan; 69(1):51-8. PubMed ID: 21911660
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography.
    Palmqvist S; Mattsson N; Hansson O;
    Brain; 2016 Apr; 139(Pt 4):1226-36. PubMed ID: 26936941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.